Literature DB >> 11272437

Laparoscopic cholecystectomy in adult patients with sickle cell disease.

R Vecchio1, E Cacciola, P Murabito, A V Gambelunghe, R Murabito, R R Cacciola, M Di Martino.   

Abstract

Cholecystectomy is a common surgical procedure performed in patients with sickle cell disease (SCD). Postoperative complications, including acute painful vaso-occlusive crisis and acute chest syndrome, have been described frequently after either traditional or laparoscopic cholecystectomy (LC). It's still not clear if preoperative blood transfusion, hyperhydration, intraoperative body temperature conservation may reduce complications rate. The Authors reviewed the charts of seven patients with SCD operated on LC for symptomatic gallbladder lithiasis and describe their perioperative management. In 3 patients preoperative endoscopic removal of stones was achieved. Five patients with HB lower than 9 g/dl and/or HbS higher than 40% were transfused preoperatively and all the patients were hyperhydrated. Intraoperative monitoring was achieved for early recognition of ventilation to perfusion mismatch and acid-base balance or temperature modifications. The Authors reported only one case of postoperative lower extremities pain. This study suggests that LC is a safe procedure in SCD if appropriate monitoring and perioperative management are achieved.

Entities:  

Mesh:

Year:  2001        PMID: 11272437

Source DB:  PubMed          Journal:  G Chir        ISSN: 0391-9005


  3 in total

1.  Laparoscopic cholecystectomy in adult patients with beta-thalassemia or sickle cell disease.

Authors:  G Marakis; T E Pavlidis; K Ballas; S Rafailidis; A Sakantamis
Journal:  Surg Endosc       Date:  2005-12       Impact factor: 4.584

2.  Laparoscopic cholecystectomy in sickle cell patients in Niger.

Authors:  Sani Rachid; Lassey James Didier; Mallam Abdou Badé; Chaibou Maman Sani; Abarchi Habibou
Journal:  Pan Afr Med J       Date:  2009-12-06

Review 3.  Sickle cell anaemia: progress in pathogenesis and treatment.

Authors:  Samir K Ballas
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.